Literature DB >> 1373531

The effect of bile duct ligation and bile diversion on FK506 pharmacokinetics in dogs.

H Furukawa1, O Imventarza, R Venkataramanan, M Suzuki, Y Zhu, V S Warty, J Fung, S Todo, T E Starzl.   

Abstract

Mongrel or beagle dogs were submitted to bile duct ligation, or to extraenteric biliary diversion by means of choledochoureterostomy. The kinetics of intravenously administered FK506 was not changed from control status two weeks after bile duct ligation, but the bioavailability of orally administered FK506 was nearly quadrupled. Following oral administration, the absorption of FK506 was highly variable. The results indicate that in dogs FK506 is absorbed from the intestine just as efficiently in the absence of enteric bile and in presence of exogenous bile salt supplement when compared with its absorption in presence of normal bile drainage. These findings with FK506 are different from those with cyclosporine after biliary obstruction or diversion and will have important practical as well as experimental ramifications.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373531      PMCID: PMC3091377          DOI: 10.1097/00007890-199204000-00002

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  11 in total

1.  Second International Workshop on FK 506. A potential breakthrough in immunosuppression: clinical implications. October 31, 1989, Barcelona, Spain. Proceedings.

Authors: 
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

2.  Pharmacokinetics of FK 506: preclinical and clinical studies.

Authors:  R Venkataramanan; A Jain; E Cadoff; V Warty; K Iwasaki; K Nagase; A Krajack; O Imventarza; S Todo; J J Fung
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

3.  Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations.

Authors:  A B Jain; R Venkataramanan; E Cadoff; J J Fung; S Todo; A Krajack; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

4.  Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine.

Authors:  R Venkataramanan; A Jain; V W Warty; K Abu-Elmagd; H Furakawa; O Imventarza; J Fung; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

5.  FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.

Authors:  T Kino; H Hatanaka; M Hashimoto; M Nishiyama; T Goto; M Okuhara; M Kohsaka; H Aoki; H Imanaka
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

6.  A highly sensitive method to assay FK-506 levels in plasma.

Authors:  K Tamura; M Kobayashi; K Hashimoto; K Kojima; K Nagase; K Iwasaki; T Kaizu; H Tanaka; M Niwa
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

7.  Role of bile and bile salts on cyclosporine absorption in dogs.

Authors:  B G Ericzon; S Todo; S Lynch; I Kam; R J Ptachcinski; G J Burckart; D H Van Thiel; T E Starzl; R Venkataramanan
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

8.  Effect of bile on cyclosporine absorption in dogs.

Authors:  R Venkataramanan; H D Perez; T Schwinghammer; G J Burckart; R J Ptachcinski; D H Van Thiel; T E Starzl
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1986-07

9.  Cyclosporine monitoring in liver transplant patients.

Authors:  W Andrews; S Iwatsuki; B W Shaw; T E Starzl
Journal:  Transplantation       Date:  1985-03       Impact factor: 4.939

Review 10.  Clinical pharmacokinetics of cyclosporin.

Authors:  R J Ptachcinski; R Venkataramanan; G J Burckart
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

View more
  6 in total

1.  Change in blood tacrolimus concentration by fluctuation of renal function in a bone marrow transplant patient.

Authors:  Masaki Sumi; Hiroki Konishi; Yoshihiro Ikuno; Nobuo Hoshino; Tokuzo Minouchi; Akira Yamaji
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Jul-Sep       Impact factor: 2.441

2.  Adverse effects of FK 506 overdosage after liver transplantation.

Authors:  M Alessiani; U Cillo; J J Fung; W Irish; K Abu-Elmagd; A Jain; S Takaya; D Van Thiel; T E Starzl
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

Review 3.  Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination.

Authors:  Christopher R Jones; Oliver J D Hatley; Anna-Lena Ungell; Constanze Hilgendorf; Sheila Annie Peters; Amin Rostami-Hodjegan
Journal:  AAPS J       Date:  2016-03-10       Impact factor: 4.009

4.  Intestinal transplantation in composite visceral grafts or alone.

Authors:  S Todo; A G Tzakis; K Abu-Elmagd; J Reyes; K Nakamura; A Casavilla; R Selby; B M Nour; H Wright; J J Fung
Journal:  Ann Surg       Date:  1992-09       Impact factor: 12.969

Review 5.  Clinical pharmacokinetics of tacrolimus.

Authors:  R Venkataramanan; A Swaminathan; T Prasad; A Jain; S Zuckerman; V Warty; J McMichael; J Lever; G Burckart; T Starzl
Journal:  Clin Pharmacokinet       Date:  1995-12       Impact factor: 6.447

6.  Tacrolimus Toxicity due to Biliary Obstruction in a Combined Kidney and Liver Transplant Recipient.

Authors:  Samuel Chan; Michael T Burke; David W Johnson; Ross S Francis; David W Mudge
Journal:  Case Rep Transplant       Date:  2017-01-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.